| HOME >> BIOLOGY >> TECHNOLOGY |
3.8.1 Transplantation of Tissues 164
3.9 Molecular Cytogenetic Testing 165
3.9.1 Hereditary Hemochromatosis 167
3.9.2 Apolipoprotein E (ApoE) Genotyping 167
3.9.3 Fragile X Syndrome (FXS) 168
3.9.4 Methylenetetrahydrofolate Reductase (MTHFR) Carrier Testing 169
3.9 5 Other Genetic Testing Procedures 170
3.10 Developments in DNA Biochips for Clinical Applications 171
3.10.1 Product Analysis 172
3.10.2 Breast Cancer DNA Arrays 174
3.10.3 eSensor DNA Detection System 175
3.11 Personalized Medicine, Pharmacogenomics and Molecular Diagnostics Testing
175
3.11.1 Coumadin (Warfarin) 178
3.12 Thrombic Disorders 180
3.13 Respiratory Virus Panel 180
3.14 HFE (Hemochromatosis) 180
3.15 Lupus 181
3.16 Down's Syndrome and Prenatal Screening 181
3.17 Molecular Diagnostics Technology Platforms and their Impact on Personalized
Medicine 182
4. Trends in Molecular Diagnostics 185
4.1 Pharmacogenomics 185
4.1.1 The Market 185
4.1.1.1 Oncology 185
4.1.1.2 Toxicogenomics 185
4.1.2 Market Influences and Forecast 186
4.2 DNA Microarrays 186
4.2.1 Techniques 191
4.2.2 The Market 191
4.2.3 Identification of Sequence SNPs 191
4.2.4 Determining Gene Expression Levels 192
4.2.4.1 Hybridization Tests 192
4.2.4.2 Oligonucleotide Probes 193
4.2.5 Molecular Diagnostics Entry into Point-of-Care (POC) Testing 193
4.3 Emerging Markets of DNA Arrays 193
4.3.1 Pharmacogenomics 195
4.3.2 Adoption of Amplified Screening Technology 195
4.3.3 Advances in Automated Testing 196
4.3.4 Increased Focus on Safety of Blood Supply 196
4.3.5 Development of Emerging Markets for NAT Technology 196
4.3.6 Cancer 197
4.3.7 Human Leukocyte Antigen (HLA) Typ
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |